Company news
Axsome Therapeutics, Inc. news in 2020
Axsome Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
Axsome Therapeutics Initiates ACCORD Phase 3 Trial of AXS-05 in Alzheimer’s Disease Agitation
December 30, 2020
Axsome Therapeutics Announces Positive Efficacy and Safety Results from the Phase 3 MOVEMENT Long-Term Trial of AXS-07 in the Acute Treatment of Migraine
December 30, 2020
Axsome Therapeutics Announces Positive Results from the COMET-SI Trial of AXS-05 in Patients with Major Depressive Disorder Who Have Suicidal Ideation
December 7, 2020
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
December 1, 2020
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
November 30, 2020
Axsome Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 4, 2020
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 3, 2020
Axsome Therapeutics and Veeva Systems Partner to Build Axsome’s Digital-Centric Commercialization™ Platform
November 3, 2020
Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 2, 2020
Axsome Therapeutics to Report Third Quarter 2020 Financial Results on November 5, 2020
October 27, 2020
Axsome Therapeutics Announces $225 Million Term Loan Facility with Hercules Capital
September 28, 2020
Axsome Therapeutics Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 Demonstrating Rapid Onset of Action and Reduced Symptom Recurrence in the Acute Treatment of Migraine
September 23, 2020
Axsome Therapeutics Announces Expedited Development of AXS-12 for the Treatment of Narcolepsy Based on FDA Breakthrough Therapy Meeting
September 20, 2020
Axsome Therapeutics Announces AXS-07 Phase 3 Migraine Trial Results Selected by the American Academy of Neurology Science Committee as Featured Presentation
September 16, 2020
Axsome Therapeutics Presents New Data from GEMINI Phase 3 Trial with AXS-05 Demonstrating Rapid and Significant Improvements in Patient-Reported Outcomes in Major Depressive Disorder
September 13, 2020
Axsome Therapeutics to Present New Data for AXS-05 in Major Depressive Disorder at the 33rd European College of Neuropsychopharmacology Congress
September 9, 2020
Axsome Therapeutics to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
September 7, 2020
Axsome Therapeutics Confirms Pivotal Status and Advancement of AXS-05 for the Treatment of Alzheimer’s Disease Agitation Based on Successful FDA Breakthrough Therapy Meeting
August 30, 2020
Axsome Therapeutics to Present Data from the CONCERT Phase 2 Trial of AXS-12 in Narcolepsy at the SLEEP 2020 Annual Meeting
August 27, 2020
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
August 19, 2020
Axsome Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
August 9, 2020
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
August 9, 2020
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
August 4, 2020
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
July 29, 2020
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
July 12, 2020
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Alzheimer’s Disease Agitation
June 25, 2020
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
May 28, 2020
Axsome Therapeutics to Host 2020 Annual Meeting of Stockholders Virtually
May 25, 2020
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020
Axsome Therapeutics to Report First Quarter 2020 Financial Results on May 8, 2020
April 29, 2020
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation
April 26, 2020
Axsome Therapeutics Announces AXS-07 Achieves Both Co-Primary Endpoints and Prevents Migraine Pain Progression in the INTERCEPT Phase 3 Trial in the Early Treatment of Migraine
April 5, 2020
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
March 29, 2020
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
March 19, 2020
Axsome Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 11, 2020
Axsome Therapeutics Announces the Promotion of Mark Jacobson to Chief Operating Officer
March 4, 2020
Axsome Therapeutics Completes Patient Enrollment in the INTERCEPT Phase 3 Trial of AXS-07 in the Early Treatment of Migraine
February 19, 2020
Axsome Therapeutics Completes Patient Randomization in the STRIDE-1 Phase 3 Trial of AXS-05 in Treatment Resistant Depression
January 21, 2020
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
January 12, 2020
Calls in 2020
Decks in 2020
- Q3 2020 Earnings Presentation
Earnings · 21 slides · Nov 5, 2020
- 2020 American Academy of Neurology Science Highlights Emerging Science Presentation
Conference · 16 slides · Sep 23, 2020
- Investor Presentation (September 2020)
Investor deck · 21 slides · Sep 16, 2020
- Q1 2020 Earnings Presentation
Earnings · 16 slides · May 8, 2020
- Technical Presentation (May 2020)
Technical · 15 slides · May 2020
- Technical Presentation (April 2020)
Technical · 23 slides · Apr 27, 2020
- Technical Presentation (April 2020)
Technical · 27 slides · Apr 6, 2020
- STRIDE-1 Phase 3 Trial of AXS-05 in TRD Topline Results Conference Call (March 2020)
Conference · 24 slides · Mar 30, 2020
- Investor Presentation (March 2020)
Investor deck · 28 slides · Mar 12, 2020
- Merger or Acquisition (January 2020)
Merger or acquisition · 16 slides · Jan 13, 2020